Skip to main content
. 2022 Feb 7;11(3):860. doi: 10.3390/jcm11030860

Table 5.

TEG/PM® and ROTEM Platelet Analysis®: specialized assays and their clinical significance [58,148].

VHA Assay Reagents Clinical Significance
TEG/PM® Kaolin TEG MA Kaolin MACK parameter is a proxy for the maximum potential function of the platelets.
Thrombin overrides inhibition via anti-platelet agents, thus kaolin-activated TEG® samples will not exhibit their effects.
Activator TEG MA Heparin, reptilase, FXIIIa MAActivator represents the isolated fibrin contribution to clot strength.
Performed alongside K-TEG®.
TEG MAAA Heparin, reptilase, FXIIIa, AA Measures AA contribution of platelet activity to clot strength.
Performed alongside K-TEG®.
TEG MAADP Heparin, reptilase, FXIIIa, ADP Measures the ADP/GPIIb/IIIa pathways’ contribution of platelet activity to clot strength.
Performed alongside K-TEG®.
ROTEM Platelet Analysis® ARATEM AA Determines GPIIb/IIIa and COX-1 receptor inhibition.
ADPTEM ADP Determines GPIIb/IIIa and ADP (P2Y12) receptor inhibition.
TRAPTEM TRAP-6 Determines GPIIb/IIIa and thrombin (PAR-1) receptor inhibition.

Abbreviations: Adenosine di-phosphate (ADP); Adenosine di-phosphate thromboelastometry (ADPTEM); Arachidonic acid (AA); Arachidonic acid thromboelastometry (ARATEM); Citrated kaolin (CK); Kaolin-TEG (K-TEG®); Maximum amplitude (MA); Rotational thromboelastometry (ROTEM); Thrombin receptor-activating peptide-6 (TRAP-6); thrombin receptor-activating peptide thromboelastometry (TRAPTEM); thromboelastography (TEG); TEG® Platelet Mapping (TEG® P/M).